JP2021533197A5 - - Google Patents
Info
- Publication number
- JP2021533197A5 JP2021533197A5 JP2021529257A JP2021529257A JP2021533197A5 JP 2021533197 A5 JP2021533197 A5 JP 2021533197A5 JP 2021529257 A JP2021529257 A JP 2021529257A JP 2021529257 A JP2021529257 A JP 2021529257A JP 2021533197 A5 JP2021533197 A5 JP 2021533197A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- complex
- transferrin receptor
- complex according
- receptor antibody
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025006544A JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713959P | 2018-08-02 | 2018-08-02 | |
| US62/713,959 | 2018-08-02 | ||
| PCT/US2019/044960 WO2020028841A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating pompe disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006544A Division JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533197A JP2021533197A (ja) | 2021-12-02 |
| JP2021533197A5 true JP2021533197A5 (https=) | 2022-08-10 |
| JPWO2020028841A5 JPWO2020028841A5 (https=) | 2022-08-10 |
Family
ID=69230844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529257A Pending JP2021533197A (ja) | 2018-08-02 | 2019-08-02 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
| JP2025006544A Pending JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006544A Pending JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210317226A1 (https=) |
| EP (1) | EP3830127A4 (https=) |
| JP (2) | JP2021533197A (https=) |
| KR (1) | KR20210054513A (https=) |
| CN (2) | CN118662653A (https=) |
| CA (1) | CA3108285A1 (https=) |
| EA (1) | EA202190417A1 (https=) |
| IL (1) | IL280483A (https=) |
| WO (1) | WO2020028841A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3635009T3 (fi) | 2017-06-07 | 2026-04-07 | Regeneron Pharma | Koostumuksia ja menetelmiä entsyymien internalisoimiseksi |
| JP7779653B2 (ja) | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20230330246A1 (en) * | 2020-05-05 | 2023-10-19 | Avidity Biosciences, Inc. | Compositions and methods of treating pompe disease |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4396231A1 (en) | 2021-09-01 | 2024-07-10 | Biogen MA Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| CA3263494A1 (en) * | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | ANTI-TFR FUSIONS: PAYLOAD AND THEIR METHODS OF USE |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004094647A2 (en) * | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| US20170182189A1 (en) * | 2014-05-23 | 2017-06-29 | Genzyme Corporation | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides |
| AU2016365834B2 (en) * | 2015-12-08 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CA3021267A1 (en) * | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| CN109310765A (zh) * | 2016-06-20 | 2019-02-05 | 领先基因生物技术股份有限公司 | 抗体-药物偶联物 |
-
2019
- 2019-08-02 JP JP2021529257A patent/JP2021533197A/ja active Pending
- 2019-08-02 CN CN202410663435.8A patent/CN118662653A/zh active Pending
- 2019-08-02 KR KR1020217005994A patent/KR20210054513A/ko active Pending
- 2019-08-02 EA EA202190417A patent/EA202190417A1/ru unknown
- 2019-08-02 EP EP19844183.4A patent/EP3830127A4/en active Pending
- 2019-08-02 CA CA3108285A patent/CA3108285A1/en active Pending
- 2019-08-02 US US17/265,016 patent/US20210317226A1/en not_active Abandoned
- 2019-08-02 WO PCT/US2019/044960 patent/WO2020028841A1/en not_active Ceased
- 2019-08-02 CN CN201980064590.5A patent/CN112912399A/zh active Pending
-
2021
- 2021-01-28 IL IL280483A patent/IL280483A/en unknown
-
2025
- 2025-01-17 JP JP2025006544A patent/JP2025071093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533197A5 (https=) | ||
| JP2021533200A5 (https=) | ||
| JP2021532832A5 (https=) | ||
| JP2021533199A5 (https=) | ||
| JP2021533198A5 (https=) | ||
| JP2025067909A5 (https=) | ||
| JPWO2020028864A5 (https=) | ||
| JPWO2020028841A5 (https=) | ||
| JPWO2020028861A5 (https=) | ||
| JPWO2020028857A5 (https=) | ||
| JP2021532831A5 (https=) | ||
| JP2022122928A5 (https=) | ||
| JPWO2020028840A5 (https=) | ||
| JPWO2020028832A5 (https=) | ||
| JPWO2022026152A5 (https=) | ||
| JPWO2018129384A5 (https=) | ||
| JPWO2022020107A5 (https=) | ||
| CN108779465A (zh) | 用于减少pd-l1表达的寡核苷酸 | |
| JPWO2021142313A5 (https=) | ||
| CN120282986A (zh) | 肌肉靶向复合物及其用于跳读dmd基因的外显子45的用途 | |
| JPWO2021142227A5 (https=) | ||
| US10155946B2 (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
| JPWO2023283531A5 (https=) | ||
| JPWO2021142307A5 (https=) | ||
| US12247047B2 (en) | Arnatar compounds and methods for enhanced cellular uptake |